FDA’s greenlighting of maternal RSV vaccine represents a major step forward in protecting young babies against the virus

by

With the Food and Drug Administration’s Aug. 21, 2023, approval of the first vaccine against respiratory syncytial virus, or RSV, for use during late pregnancy, the U.S. will soon have a major new tool at its disposal to protect infants against the highly contagious virus.

Leave A Comment

Your email address will not be published. Required fields are marked *